Angimmune

Angimmune is a private, pre-revenue biotech focused on a novel immunotoxin therapy, Resimmune (A-dmDT390-bisFv(UCHT1)), which targets the CD3 receptor on T-cells. Its lead indication is Cutaneous T-Cell Lymphoma (CTCL), where it has received FDA Fast Track and Orphan Drug designations. The company is exploring broader applications in autoimmune disorders, combination cancer immunotherapy, and a potentially transformative induction protocol to prevent antibody-mediated rejection in organ transplantation. With a short, four-day dosing regimen, the therapy offers a differentiated approach to modulating the immune system.

Proprietary diphtheria toxin (DT390)-based immunotoxin platform expressed in Pichia pastoris. It utilizes bivalent single-chain antibody fragments (bisFv) to target cell surface receptors (e.g., CD3) for high-affinity binding, internalization, and targeted cell killing, with subsequent immunomodulatory effects.

In CTCL, Resimmune competes with other targeted therapies, histone deacetylase inhibitors, and newer biologics, but its short-course, immunomodulatory mechanism is differentiated. In transplantation, it would face competition from standard non-depleting and depleting induction agents (e.g., basiliximab, anti-thymocyte globulin), but its proposed goal of inducing B-cell tolerance is a novel and potentially superior approach. In IO combinations, it enters a fiercely competitive space with numerous mechanisms aimed at enhancing checkpoint inhibitor efficacy.